# Trial of Ginsenoside Compound K (GCK) Tablet in Patients With Rheumatoid Arthritis

> **NCT03755258** · PHASE1 · UNKNOWN · sponsor: **Zhejiang Hisun Pharmaceutical Co. Ltd.** · enrollment: 128 (estimated)

## Conditions studied

- Early Rheumatoid Arthritis

## Interventions

- **DRUG:** GCK 100 mg + Placebo 200 mg
- **DRUG:** GCK 200 mg + Placebo 100 mg
- **DRUG:** GCK 300 mg
- **DRUG:** Placebo 300mg

## Key facts

- **NCT ID:** NCT03755258
- **Lead sponsor:** Zhejiang Hisun Pharmaceutical Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-03-16
- **Primary completion:** 2019-07-11
- **Final completion:** 2019-12-11
- **Target enrollment:** 128 (ESTIMATED)
- **Last updated:** 2018-11-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03755258

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03755258, "Trial of Ginsenoside Compound K (GCK) Tablet in Patients With Rheumatoid Arthritis". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03755258. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*